Tumor Selectivity

MTX-101’s selectivity profile is supported by:
• Differential transporter overexpression in tumor versus normal tissue
• Reduced reliance of normal cells on the targeted pathway
• Favorable therapeutic index in preclinical toxicology models

This selective dependency supports a precision oncology strategy focused on biomarker-defined populations.